PREVU* life insurance trial
This article was originally published in The Tan Sheet
Executive Summary
A 25,000-patient study evaluating PREVU* LT in the life insurance testing market is expected to begin in the second quarter of 2005, International Medical Innovations announces May 10. The PREPARE study (PREVU Predicts Atherosclerosis Risk & Events) will test life insurance applicants with the product and compare the results to "traditional risk assessment measures," IMI says. PREVU* LT is the lab-processed version of the company's skin sterol test, which measures cholesterol levels by testing skin tissues. Entering the insurance market offers an opportunity to the firm because a "significant number" of the 13.5 mil. individuals who purchased life insurance policies in 2003 did not have a cardiovascular disease assessment, IMI says. The company reached a licensing agreement last year with McNeil's consumer division that includes working to develop an OTC version of the product (1"The Tan Sheet" June 7, 2004, p. 10)...
You may also be interested in...
McNeil Reaches Consumer Cholesterol Testing Licensing Deal With IMI
McNeil Consumer Health is seeking to leverage the potential Rx-to-OTC switch of J&J/Merck's Mevacor (lovastatin) with an agreement to license International Medical Innovations' predictive tests for coronary artery disease (CAD)
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.